



**C4X Discovery Holdings plc**  
("C4XD", "C4X Discovery" or the "Company")

### **Notice of Results**

**9 November 2018** - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, will be announcing its full year results for the year ended 31 July 2018 on **Wednesday 21 November 2018**.

A webcast and conference call for analysts will be held at **11:30am GMT** on the day of the results. Presentation slides will be made available on the Company website in advance of the call.

**--ENDS--**

#### **For further information, please contact:**

##### **C4X Discovery Holdings plc**

Clive Dix, Chief Executive Officer

+44 (0)7801 865 803

##### **Panmure Gordon (UK) Limited (NOMAD and Broker)**

+44 (0)20 7886 2500

Freddy Crossley, Emma Earl (Corporate Finance)

James Stearns (Corporate Broking)

##### **Consilium Strategic Communications**

Mary-Jane Elliott, Chris Gardner, Matthew Neal

+44 (0)203 709 5700

#### **About C4X Discovery**

C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.

C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3<sup>®</sup>) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4XD's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. This provides new and unprecedented insight into the behaviour of drug molecules, enabling the production of potent selective compounds faster and more cost effectively than the industry standard.

C4X Discovery is advancing its in-house pipeline that is primarily focused on the high value therapeutic areas of inflammation, neurodegeneration and cancer (including immuno-oncology) with a number of new drug candidates identified and further progress made towards the pre-clinical licensing discussions. In selecting new targets and executing new drug discovery programmes, C4X Discovery focuses on high-value disease areas that are

the subject of significant licensing activity and will continue to also maximise value from opportunistic areas such as addiction and diabetes. The Company recently signed a licensing agreement with Indivior for a pre-clinical addiction programme worth up to \$294m.

The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD to reach multiple value inflexion points since IPO. For additional information please go to: [www.c4xdiscovery.com](http://www.c4xdiscovery.com)